Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
In PNAS this week: intronic STAT3 splice site linked to autosomal dominant primary immunodeficiency condition, human B lymphocyte changes following Epstein-Barr virus exposure, and more.
The Singapore-based company will debut a system at AACC that performs real-time PCR flu A/B testing in less than 20 minutes for the cost of a lateral flow test.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
In PLOS this week: reference bias effects in ancient genomics, tsetse fly genetic diversity, and more.
In Science this week: gut microbiome influences the development and function of skeletal muscle in mice, and more.
Qiagen reported year-over-year net sales of 1 percent, or 5 percent at constant exchange rates ahead of its planned Q2 earnings release next week.
Following a South Korean distribution agreement signed in May, the deal further expands the reach of NanoCellect's microfluidic-based cell handling products.
Labs in China can now use the Cobas EGFR Mutation Test v2 with either tissue or plasma samples as a CDx for three Roche oncology drugs in NSCLC patients.
The teams used different sequencing approaches — one using long reads and the other short reads — to uncover repeat expansions in people with a rare disease.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.